409 POSTER Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer

2005 ◽  
Vol 3 (2) ◽  
pp. 114-115
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Newly Diagnosed ◽  
Hormonal Receptor

Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 764-764 ◽  
Author(s):  
F. Penault-Llorca ◽  
A. Vincent-Salomon ◽  
M. C. Mathieu ◽  
V. Trillet-Lenoir ◽  
D. Khayat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Newly Diagnosed ◽  
Hormonal Receptor

scholarly journals Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Anna-Maria Larsson ◽  
Pär-Ola Bendahl ◽  
Kristina Aaltonen ◽  
Sara Jansson ◽  
Carina Forsare ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Thymidine Kinase ◽  
Prospective Observational Study ◽  
Rapid Development ◽  
Metastatic Breast ◽  
Newly Diagnosed ◽  
Monitoring Tools ◽  
Serial Evaluation

AbstractThe rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its activity correlates to outcome in cancer patients. The aim of this study was to evaluate serum TK1 activity (sTK1) levels in MBC patients as a tool for prognostication and treatment monitoring. 142 women with MBC scheduled for 1st line systemic treatment were included in a prospective observational study. sTK1 was measured at baseline (BL) and at 1, 3 and 6 months and correlations to progression-free and overall survival (PFS, OS) evaluated. High sTK1 levels (above median) correlated to worse PFS and OS at BL, also after adjusting for other prognostic factors. sTK1 levels were significantly associated with PFS and OS measured from follow-up time points during therapy. Changes from 3 to 6 months during therapy significantly correlated to PFS and OS, whereas early changes did not. We could demonstrate sTK1 level as an independent prognostic factor in patients with newly diagnosed MBC. Changes in sTK1 levels from 3 to 6 months correlated to PFS and OS. Future studies of sTK1 are warranted to further define its clinical utility.

Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11591-e11591
Author(s):  
Pui San Tan ◽  
Benjamin Haaland ◽  
Alberto J. Montero ◽  
Gilberto Lopes
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Metastatic Breast Cancer ◽  
Combination Therapy ◽  
Meta Analysis ◽  
Metastatic Breast ◽  
Line Treatment ◽  
First Line ◽  
Hormonal Receptor ◽  
First Line Treatment

e11591 Background: Emerging resistance to single agent aromatase inhibitors (AI) or fulvestrant as first line treatment for postmenopausal women with advanced hormonal receptor positive breast cancer calls for alternative therapeutic options. This meta-analysis studies the effectiveness of combination therapy with fulvestrant and an AI, as compared to an AI alone in first line treatment of postmenopausal patients with hormonal receptor positive relapsed or metastatic breast cancer. Methods: Literature search was performed using PubMed, Google Scholar, Embase, ASCO and ESMO to search for studies published during the last 10 years using relevant keywords. Two prospective randomized clinical trials were found to fulfill the search criteria for combination of fulvestrant + AI vs. AI alone (both studied anastrozole in combination with fulvestrant). Meta-estimates were calculated by combining study estimates using the DerSimonian and Laird random effects model. The linear mixed-effects model was used to generate 95% prediction intervals for study-specific hazard and odds ratios. Results: Pooled hazard ratio for progression free survival was 0.88 (95% CI 0.72-1.09, 95% prediction interval [PI] 0.65-1.21). Pooled HR for overall survival was 0.88 (95% CI 0.72-1.08, 95% PI 0.68-1.14). Pooled odds ratio for response rate was 1.13 (95% CI 0.79-1.63, 95% PI 0.78-1.65). Conclusions: Pooled results showed a small, non-statistically significant, improvement in progression-free and overall survival. These results do not support the use of combination therapy with fulvestrant and anastrozole in the first line treatment of postmenopausal patients with hormonal receptor positive relapsed or metastatic breast cancer.

scholarly journals Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Nicole Meyer ◽  
Yanni Hao ◽  
Xue Song ◽  
Nianwen Shi ◽  
William Johnson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
De Novo ◽  
Metastatic Breast ◽  
Adult Women ◽  
Targeted Agents ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Office Visits ◽  
Outpatient Services

Objective. To compare healthcare utilization (HCU) and costs of women newly diagnosed with metastatic breast cancer (mBC) by receipt of HER2-targeted agents (H2T) and among H2T subgroups.Methods. Adult women newly diagnosed with mBC (index date) during 2008–2012 were followed until enrollment end or inpatient death. Study cohorts were antineoplastic ± H2Ts, and no treatment; and subgroups of H2T patients stratified by receipt of hormonal therapy (HT+/HT−), byde novoversus recurrent disease status, and by age group. All-cause (ALL) and breast cancer related (BCR) HCU and costs (in 2012 dollars) were estimated using a generalized linear model.Results. Of 18,059 women, 14.6% were H2T users 71.1% nonusers, and 14.3% untreated. No treatment patients had the highest ALL and BCR inpatient HCU, and ALL emergency room HCU. H2Ts users had the highest ALL and BCR office visits, lab and diagnostic radiology, radiation treatments, other outpatient services, and prescription antineoplastics. Adjusted ALL and BCR costs were the highest for H2T users and, in H2T subgroups, higher for HT—versus HT+ andde novoversus recurrent, and declined with older age.Conclusions. Receipt of H2Ts was associated with greater levels of ALL and BCR HCU and costs. H2T subgroups ofHT-,de novo, and younger age had higher HCU and costs, possibly indicating more aggressive treatments.

Sign in / Sign up

Export Citation Format

Share Document